SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced the pricing of an underwritten public offering of 5,454,545 shares of its common stock at a public offering price of $5.50 per share. The offering is expected to close on or about January 23, 2018, subject to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 818,181 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Obalon Therapeutics.
UBS Investment Bank, Canaccord Genuity and Stifel are acting as joint book-running managers for the offering. BTIG is acting as a co-manager.
The offering is being made pursuant to a shelf registration statement that was declared effective by the Securities and Exchange Commission (SEC) on November 17, 2017. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, the final prospectus supplement and the accompanying prospectus, relating to the offering may also be obtained by contacting UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by telephone at (888) 827-7275 or by e-mail at firstname.lastname@example.org; Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110 or by telephone at (617) 371-3900 or by e-mail at email@example.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at (415) 364-2720 or by email at firstname.lastname@example.org.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Obalon Therapeutics’ expectations regarding the completion, size and timing of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering. More information about the risks and uncertainties faced by Obalon Therapeutics is contained in the section captioned “Risk factors” in the preliminary prospectus supplement related to the public offering filed with the SEC. Obalon Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760.607.5103
Office: +1 646.517.4220
Source:Obalon Therapeutics, Inc.